Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience.
Microb Drug Resist
; 27(9): 1167-1175, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1406451
ABSTRACT
Background:
The aim of this study was to assess the drivers of multidrug-resistant (MDR) bacterial infection development in coronavirus disease 2019 (COVID-19) and its impact on patient outcome.Methods:
Retrospective analysis on data from 32 consecutive patients with COVID-19, admitted to our intensive care unit (ICU) from March to May 2020. Outcomes considered were MDR infection and ICU mortality.Results:
Fifty percent of patients developed an MDR infection during ICU stay after a median time of 8 [4-11] days. Most common MDR pathogens were carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii, causing bloodstream infections and pneumonia. MDR infections were linked to a higher length of ICU stay (p = 0.002), steroid therapy (p = 0.011), and associated with a lower ICU mortality (odds ratio 0.439, 95% confidence interval 0.251-0.763; p < 0.001). Low-dose aspirin intake was associated with both MDR infection (p = 0.043) and survival (p = 0.015). Among MDR patients, mortality was related with piperacillin-tazobactam use (p = 0.035) and an earlier onset of MDR infection (p = 0.042).Conclusions:
MDR infections were a common complication in critically ill COVID-19 patients at our center. MDR risk was higher among those dwelling longer in the ICU and receiving steroids. However, MDR infections were not associated with a worse outcome.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
Opportunistic Infections
/
Acinetobacter Infections
/
Klebsiella Infections
/
Drug Resistance, Multiple, Bacterial
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Microb Drug Resist
Journal subject:
Microbiology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
MDR.2020.0489
Similar
MEDLINE
...
LILACS
LIS